Clinical Trials Logo

Clinical Trial Summary

Among the psychiatric symptoms observed in the premotor phase of Parkinson's disease (PD) and/or in "de novo" patients, apathy is relatively frequent (estimated to 23%). However, the neuropathological bases of apathy are still unknown. However, recent data suggests that apathy could be linked to a more specific dopaminergic denervation in the ventral striatum.

Rasagiline increases the bioavailability of striatal endogenous dopamine by blocking the MAO-B. Some recent data suggest rasagiline could be effective to improve apathy in Parkinson's disease.

The primary outcome is to demonstrate a significant reduction of apathy using the Lille apathy rating scale (LARS) in drug naive patients with early diagnosed Parkinson's disease, using a treatment by rasagiline.


Clinical Trial Description

Study design :

Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France

Population :

50 drug-naïve patients with Parkinson's disease, with apathy. 2 groups : 25 patients with placebo and 25 patients with rasagiline.

3 visits

- Visit 1 : inclusion / randomisation/ first study medication dispensation

- Visit 2 (1.5 month after V1) : first evaluation and second study medication dispensation.

- Visit 3 (3 months after V1, final visit) : second evaluation ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01765257
Study type Interventional
Source University Hospital, Clermont-Ferrand
Contact Patrick LACARIN
Phone 04 73 75 11 95
Email placarin@chu-clermontferrand.fr
Status Not yet recruiting
Phase Phase 4
Start date June 2013
Completion date March 2015

See also
  Status Clinical Trial Phase
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT03293537 - Dementia Associated Apathy. N/A
Terminated NCT01825577 - Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia. Phase 4
Withdrawn NCT00792662 - Improving Function, Quality of Life, Glycemia in Diabetics With Dementia Phase 4
Recruiting NCT03590327 - Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment N/A
Completed NCT02190084 - Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia Phase 4
Completed NCT05808530 - Cognitive Stimulation Therapy N/A
Completed NCT00767091 - Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia Phase 3
Not yet recruiting NCT06184165 - Stratifying Psychoses for Personalized REpetitive TMS in Persistent NEgative Symptoms Alleviation N/A
Terminated NCT02915484 - Transcranial Direct Current Stimulation (tDCS) in Chronic Post-Stroke Apathy N/A
Recruiting NCT01885806 - Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease Phase 2
Recruiting NCT01689181 - Apathy in Schizophrenia N/A
Active, not recruiting NCT02786667 - Non Motors Aspects in De Novo Parkinson's Disease Phase 3
Completed NCT01914965 - Apathy Cure Through Bupropion in Huntington's Disease Phase 2
Completed NCT01117181 - Apathy in Dementia Methylphenidate Trial (ADMET) Phase 2
Terminated NCT05182151 - Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
Completed NCT00844090 - The Role of Apathy in Glycemic Control N/A
Completed NCT01172145 - Treatment of Apathy in Alzheimer's Disease With Modafinil Phase 3
Completed NCT00456820 - Wellbutrin XL Effects on SSRIs Induced Changes Phase 4
Recruiting NCT04917237 - Non-disabling Ischemic Cerebrovascular Event With Apathy